Table 4 General information about LPV/r treatment of pregnant women

From: Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials

 

Age at delivery  (year)

Baseline CD4+ count  (cells/mm3)

Baseline viral load (log10 copies/mL)

Vaginal delivery (%)

MTCT (%)

PD (%)

LBW (%)

Roberts SS et al.19

13–48

NA

NA

NA

NA

13.4

19.2

Senise J et al.20

29.4 (16–41)#

289 (13–811)*

4.28 (0– ≥ 5.88)*

11

0.8

25.0

20.3

de Vincenzi I21

27 (24–31)*

336 (282–408)∧

4.23 (3.66–4.75)∧

89

1.8

13.2

11.4

Azria E et al.22

32.4 ± 5.0$

361 (8–858)*

3.6 (<1.7–5.4)*

45

1.0

21.0

17.0

Peixoto MF et al.23

29.6 ± 5.5$

486.1 ± 292.7 $

2.6 ± 1.0$

NA

0.6

9.8

20.2

Peixoto MF et al.23

27.1 ± 6.4$

535.4 ± 303.9 $

3.0 ± 0.7$

NA

0.7

8.7

15.9

Villatoro CM et al.24

26 (16–43)*

329 (2–1034)#

4.82 (0–6.26)#

4

1.4

10.6

NA

Shapiro RL et al.25

25

403 (297–514)∧

3.96 (3.34–4.60)∧

NA

NA

14.8

13.1

  1. #Mean (range);
  2. *median (range);
  3. ∧median (quartiles);
  4. $mean ± standard deviation.
  5. MTCT: mother-to-child transmission; PD: preterm delivery (<37 weeks gestation); LBW: low birth weight (<2,500 g).
Back to article page